Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection

Completed · Phase 3 · Has a placebo group

Conditions studied: Healthy Volunteers

In brief

This randomized, double blind, placebo controlled study aims to establish the impact of the oral supplement, Immulina TM, on enhancing host resilience to the effects of viral influenza infection in humans.

Key facts

Study ID
NCT05447078
Run by
University of Mississippi Medical Center
People needed
492
Starts
2022-07-01
Expected to finish
2025-12-08
Last updated by the study team
2026-07-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.